Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Chung

Diagnostic Radiology San Diego, CA Medical Doctor

NPI 1508878752 CMS profile 918590

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$746,946

325 records reported · program years 2019–2025

Research payments

$11,406

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Chung of San Diego, CA is reported in the CMS Open Payments database as having received $746,946 across 325 general payments and $11,406 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $187,282 98
2025 Research $11,406 8
2024 General $165,849 50
2023 General $167,587 63
2022 General $94,470 38
2021 General $26,626 16
2020 General $32,849 10
2019 General $72,282 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Chung
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Jonathan Chung were reported at $187,282. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Jonathan Chung Diagnostic Radiology median Middle half National median
2019 $72,282 $108 $29–$318 $163
2020 $32,849 $65 $21–$252 $114
2021 $26,626 $92 $24–$292 $132
2022 $94,470 $104 $29–$294 $149
2023 $167,587 $110 $29–$337 $160
2024 $165,849 $113 $30–$356 $164
2025 $187,282 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $463,119 126 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $202,921 128 payments
  3. Genentech USA, Inc. $26,753 22 payments
  4. AstraZeneca UK Limited $22,151 13 payments
  5. Olympus America Inc. $11,917 17 payments
  6. Roche Products Limited $6,474 3 payments
  7. BeiGene USA, Inc. $4,875 3 payments
  8. AbbVie, Inc. $3,850 4 payments
  9. Boehringer Ingelheim International GmbH $2,700 2 payments
  10. BeOne Medicines USA, Inc. $1,500 1 payment
  11. Other $685 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $585,002 166 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $133,699 45 payments
  3. Travel and Lodging $24,233 58 payments
  4. Food and Beverage $4,012 56 payments
Products named General payments · program years 2019–2025
  1. ENHERTU Oncology $417,274 113 payments
  2. OFEV Respiratory $48,092 23 payments
  3. Datroway $45,845 13 payments
  4. OFEV Respiratory $17,525 6 payments
  5. Spiration Valve System $12,393 18 payments
  6. Esbriet $10,511 9 payments
  7. ENHERTU Oncology $5,187 5 payments
  8. OFEV Oncology $1,200 1 payment
  9. IMFINZI $125 1 payment
  10. AMPLATZER AMULET $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $11,406 8 payments

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$75,274

Medicare's payments for the services billed

Medicare patients

1,998

Average age 73

Services billed

2,471

1,004 women, 994 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 39%
Cancer 36%
Diabetes 35%
Chronic kidney disease 35%
Heart failure 34%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $123,165
$123,165 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $16,025
$16,025 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record